Elekta (EKTA) CMD 2026 summary
Event summary combining transcript, slides, and related documents.
CMD 2026 summary
18 Jun, 2026Strategic Direction and Innovation
Turnaround strategy emphasizes innovation-driven growth, operational excellence, and a simplified, decentralized structure, with a leaner workforce and over SEK 500 million in annual cost savings.
Committed to investing ~10% of revenue in R&D, prioritizing adaptive, image-guided, and precision radiotherapy, with rapid, continuous product releases and major upgrades in imaging, workflow, and AI-enabled software.
Adaptive radiotherapy and hypofractionation are central, enabling faster, more precise treatments and supporting clinics in treating more patients efficiently.
Software and service expansion, including SaaS and integrated workflow solutions, are key levers for margin improvement and recurring revenue.
Enhanced interoperability, upgradability, and customer-centric innovation across the product suite, with a focus on market-driven needs.
Product and Innovation Agenda
Major product launches planned, including Evo and Unity Pro linacs, Iris high-definition imaging, and integrated 6D table, aiming to double patient throughput and support advanced protocols.
Software advances include 10x faster treatment planning, remote collaboration, and enhanced oncology information systems.
Innovation agenda aims to boost clinic productivity, reduce treatment times, and enable adaptive workflows.
Regional Growth and Market Positioning
Europe: Strong replacement cycle opportunity with 1,000 aging Linacs, focus on Evo platform, recurring revenue from service and SaaS, and improved commercial execution.
Americas: Targeting a turnaround in the U.S. via adaptive therapy solutions, improved reimbursement for complex treatments, and high service attachment rates; aiming for mid to high-single digit CAGR and increased competitive wins.
China: Market recovering post anti-corruption campaign, with ~40% share; priorities include localization, ecosystem partnerships, and China-tailored products like Harmony Pro.
Emerging markets: Intensified competition expected, but tailored product strategies and premium positioning aim to defend and grow share.
All regions emphasize service and software expansion, higher attach rates, and recurring revenue models.
Latest events from Elekta
- Profitability and cash flow surged on cost savings, despite SEK sales decline and impairments.EKTA
Q4 25/261 Jun 2026 - Adjusted gross margin rose to 38.3% as restructuring to yield SEK 500M+ savings from Q1.EKTA
Q3 25/2629 Apr 2026 - Four strategic priorities and a new model target SEK 500M+ savings and global growth.EKTA
Strategy update9 Apr 2026 - Sales up 5% year-over-year, but Q4 declined; margin recovery expected in H2 2024/25.EKTA
Q4 23/2431 Jan 2026 - Net sales up 1% with strong U.S. growth and a major Mexico order; margin recovery expected.EKTA
Q1 24/2523 Jan 2026 - Sales and margins declined, but new products and cost savings are set to boost performance.EKTA
Q2 24/2512 Jan 2026 - AI-driven adaptive radiotherapy and software boost growth, margins, and global adoption.EKTA
Investor update10 Jan 2026 - Record cash flow and European growth offset US and China weakness; margin guidance lowered.EKTA
Q3 24/2527 Dec 2025 - Margins improved, cash flow strengthened, and major cost-saving actions launched.EKTA
Q2 25/2626 Nov 2025